Executive Officers and Division Heads

Robert J. Coury is the executive chairman of Mylan. Under his leadership, Mylan has been transformed into the third largest generics and specialty pharmaceutical company in the world, serving customers in more than 150 countries and territories.

Coury was elected to Mylan's board of directors in February 2002, having served since 1995 as a strategic advisor to the company. He became the board's vice chairman shortly after his election and was made CEO of the company in September of that same year, a post he held through 2011.

In 2007, Mylan, under Coury's leadership, took the decision to become global. At the time, Mylan was the third largest generics manufacturer in the U.S. By purchasing India-based Matrix Laboratories, a major producer of active pharmaceutical ingredients, and acquiring the generics business of Europe-based Merck KGaA, Mylan catapulted to the No. 3 position in the industry worldwide. The acquisition of the former "Merck Generics" gave the company unprecedented scale in many critical areas, including an extensive and unique international commercial footprint.

Prior to these game-changing acquisitions, from 2002-2007, Coury helped further position Mylan to prosper long-term in a consolidating industry marked by increasing competition and growing demand worldwide for high quality, affordable pharmaceuticals. During this pre-globalization period, the company more than doubled its manufacturing capacity; expanded investment in research and development; and maintained Mylan's strong industry leadership on key issues, working with policymakers to help create a more level playing field for producers of generic drugs.

Before Mylan, Coury was the principal of Coury Consulting, a boutique business advisory firm he formed in 1989, and The Coury Financial Group, a successful financial and estate planning firm. Coury earned a Bachelor of Science degree in industrial engineering from the University of Pittsburgh.

Heather Bresch is chief executive officer of Mylan, one of the largest generics and specialty pharmaceutical companies in the world. She also serves on the company's board of directors.

Mylan's mission is to provide the world's 7 billion people access to high quality medicine. Over the course of her 20-year career at the company, Bresch has been a champion of initiatives and policy changes aimed at removing barriers that hinder patient access to high quality medicine. She has testified before the U.S. Congress and the U.S. Food and Drug Administration, among other institutions, on issued related to access to medicine.

Some of Bresch's key policy priorities include working to ensure that everyone living with HIV/AIDS has access to treatment and advocating for treatment soon after diagnosis to ensure better health outcomes, reduce HIV transmissions and create long-term cost savings. As part of this effort, Bresch has worked to call attention to access issues in developing countries for patients in need of antiretroviral (ARV) treatment for HIV/AIDS. Further, she has helped position Mylan as a leader in the development and manufacture of ARVs. Today, approximately one out of three people in the developing world being treated for HIV/AIDS depends on a Mylan ARV product.

In other efforts to drive access to medicine, Bresch is actively advocating for the implementation of a viable abbreviated approval pathway for safe and effective generic versions of biologic drugs to provide patients with access to lower-cost versions of life-saving products. She also is working to increase generic drug utilization around the world, particularly in markets where generic utilization rates remain relatively low.

In addition, Bresch is passionate about increasing awareness of food allergies, which can sometimes lead to a life-threatening allergic reaction, called anaphylaxis. She is active in increasing awareness of the risk, symptoms of anaphylaxis, encouraging preparedness to respond when anaphylaxis occurs, and having immediate access to Epinephrine auto-injectors, as Epinephrine is considered the first-line treatment for anaphylaxis.

Bresch also has been a leading advocate for ensuring one quality standard for all drugs sold in the U.S., regardless of where the product is made. As part of this effort, she was instrumental in the development of the Generic Drug User Fee Act (GDUFA), which would ensure timely and predictable review of abbreviated new drug applications and provide inspection certainty for all foreign and domestic facilities. Bresch also is strongly advocating for a needed change to the Federal Food, Drug and Cosmetic Act of 1938 (FDCA) in order to arm the U.S. Food and Drug Administration with the necessary resources and authority to regularly inspect foreign plants. The FDCA today only mandates regular inspection of domestic facilities.

Earlier in her career, Bresch played a vital role in the passage of the 2003 Medicare Modernization Act, a congressional revision to the Hatch-Waxman Act of 1984, which helped to ensure consumer access to affordable pharmaceuticals.

Throughout her career with Mylan, Bresch has held roles of increasing responsibility in more than 15 functional areas. Prior to becoming CEO, Bresch served as Mylan's president, where she was responsible for the day-to-day operations of the company. Before that, she served as Mylan's chief operating officer and chief integration officer, leading the successful integration of two transformational and game-changing international acquisitions – Matrix Laboratories and Merck KGaA's generics business. In addition, Bresch has served as head of Mylan's North America operations.

Bresch has served two consecutive terms as chairman of the Generic Pharmaceutical Association and one term as its vice chairman. Bresch earned her undergraduate degree from West Virginia University.

Rajiv Malik is Mylan's president, overseeing the day-to-day operations of the company. Malik has held important leadership positions at Mylan since January 2007, when the company acquired a controlling stake in Matrix Laboratories Limited (now Mylan Laboratories Limited), one of the world's largest suppliers of active pharmaceutical ingredients. At the time of the acquisition, Malik was Matrix's chief executive officer.

Before becoming president, Malik was Mylan's executive vice president and chief operating officer, responsible for the company's global research and development (R&D) centers, and manufacturing and distribution units. Earlier he served as the executive vice president in charge of Mylan's Global Technical Operations, overseeing the company's generic biologics efforts as well as initiatives related to emerging markets. Malik has played a key role in enhancing and rationalizing Mylan's global supply chain and expanded product pipeline, as well as leveraging Mlyan in India's capabilities across the company.

Malik has worked for more than 28 years in the global generic pharmaceutical industry. Prior to joining Matrix in 2005, Malik was head of Global Development ant Regulatory at Sandoz. He started his R&D career at Ranbaxy Laboratories, rising to head of Generics R&D.

Malik earned his master's degree in pharmaceutical technology from Punjab University, India, and has more than 60 process patents to his credit.

John D. Sheehan is Mylan's chief financial officer (CFO), a position he has held since April 2010. Sheehan leads Mylan's global finance functions, including accounting and control, financial planning and analysis, treasury, investor relations and tax. Sheehan also maintains responsibility for leading Mylan's global IT functions.

Sheehan brings nearly 30 years of professional experience in global corporate finance, accounting, auditing and management. He has held numerous leadership positions, most recently as CFO for Detroit-based Delphi Automotive LLP, a global supplier of automotive electronics and technologies, where he led all aspects of the company's global finance function. Prior to the CFO role, Sheehan held several senior management positions at Delphi, including chief restructuring officer and chief accounting officer and controller.

Before Delphi, Sheehan was a partner at KPMG, a global professional accounting firm, where he worked for 20 years in multiple roles of increasing responsibility and exposure. While at KPMG, Sheehan gained extensive international manufacturing experience and auditing and accounting skills. He also worked in London, Frankfurt, Stuttgart and the U.S. with a variety of KPMG's top-tier clients.

Sheehan earned a bachelor's degree in accounting from St. Bonaventure University, St. Bonaventure, N.Y. He is a member of the American Institute of Certified Public Accountants. Sheehan also served as president of the board of directors for the International School of Stuttgart, Germany, from 1999-2001.

Harry A. (Hal) Korman is Mylan's chief operating officer. Previously, he was president, North America, overseeing the growth and development of Mylan Pharmaceuticals Inc. (MPI), Mylan's generics business in the United States; Genpharm Inc., the former Canadian subsidiary of Merck Generics and fourth-largest generics company in Canada; and UDL Laboratories Inc., the U.S. leader in unit dose packaging.

Earlier, Korman held the positions of president of MPI and senior vice president of Mylan Laboratories Inc. Since joining Mylan through its acquisition of UDL Laboratories in 1996, Korman has held several positions of increasing responsibility, including president of UDL and vice president of Sales and Marketing for MPI. He was a Sales Representative for Berlex Laboratories Inc. for approximately eight years.

Korman earned a bachelor's degree in marketing/distributive education from the University of Wisconsin.

Didier Barret is Mylan's president of the Europe, Middle East and Africa (EMEA) region, a position he has held since Mylan's acquisition of Merck Generics in October 2007. Barret oversees Mylan's operations throughout the EMEA region.

At Merck Generics, Barret most recently served as region director, EMEA, reporting to the CEO. He was promoted to that position in 2004 following his role as area director for Southern Europe, where he was responsible for operations in France, Belgium, Italy, Spain and Portugal. He established Merck Generics' first operations in France in 1995, growing the business to exceed €341 million in annual sales by 2006. Prior to this, Barret held several positions within Merck's branded division, including sales and marketing in the United Kingdom and France.

From 2010 to 2011, Barret served as the chairman and president of the European Generics Medicines Association.

Barret earned a doctorate degree in pharmacy from the University of Grenoble, France, and an MBA from the Lyon Business School, France.

Anthony Mauro is Mylan's president, North America, and president of Mylan Pharmaceuticals Inc. In his 15 years at Mylan, Mauro has held roles of increasing responsibility across the company's business units, including president of Mylan Pharmaceuticals, chief operating officer for Mylan Pharmaceuticals ULC in Canada, vice president of Strategic Development, North America, and vice president of Sales, North America.

In 2012, Mauro was elected to serve as chairman of the Generic Pharmaceutical Association's (GPhA) board of directors. GPhA is an association that represents the world's leading generic drug manufacturers and suppliers. Mauro's election to this role further supports Mylan's mission to impact the future through passionate global leadership on the important issues and policies that shape the generic pharmaceuticals industry. Mauro's term as chairman of GPhA will last for one year. Previously, he served two one-year terms as the vice chairman of the association.

Mauro is also a director and officer of the American Traditions Insurance Company (ATIC) and a member of the board of directors at West Virginia University's Graduate School of Business and Economics.

Mauro earned a bachelor's degree in business administration, with a specialization in finance, and a master's degree in business administration, from West Virginia University.